The use of a removable stent in patients with prostate cancer and obstruction.
OBJECTIVE
A second generation temporary stent (ProstaCoil*) was inserted into the prostatic urethra of patients with obstruction due to prostate cancer to allow spontaneous voiding during hormonal therapy given to decrease the size of the prostatic mass.


METHODS
The stent was inserted under fluoroscopic guidance using topical anesthesia in 27 patients (mean age 77 years) who presented with urinary retention due to advanced carcinoma of the prostate. All patients underwent operative or nonoperative hormonal therapy shortly after insertion of the stent.


RESULTS
Followup of our patients was 3 to 48 months after stent removal and 15 void spontaneously. In 6 patients the stent was removed 9 to 19 months after insertion due to slow regression of the prostatic mass. Two of these patients required transurethral resection of the prostate and in 3 a new stent was inserted because of recurrent obstruction. two recently treated patients await stent removal and 3 died before removal of the stent. During followup no patient had urinary infection, either with the stent indwelling or after its removal.


CONCLUSIONS
Temporary internal stenting of the prostate should be the treatment of choice for relieving obstruction during hormonal therapy given for prostate cancer.
Yachia
D
D
Department of Urology, Hillel Yaffe Medical Center, Hadera, Israel.
Aridogan
I A
IA
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D002408:Catheters, Indwelling; D004867:Equipment Design; D005485:Flutamide / Q000627:therapeutic use; D005500:Follow-Up Studies; D017273:Goserelin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000150:complications* / Q000628:therapy; D015607:Stents; D013997:Time Factors; D014521:Urethra; D001748:Urinary Bladder Neck Obstruction / Q000209:etiology / Q000628:therapy*; D014546:Urinary Catheterization; D016055:Urinary Retention / Q000209:etiology / Q000628:therapy*
D018931:Antineoplastic Agents, Hormonal; D017273:Goserelin; D005485:Flutamide